Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

نویسندگان

  • S Jose
  • K Quinn
  • D Dunn
  • A Cox
  • C Sabin
  • S Fidler
  • Jonathan Ainsworth
  • Sris Allan
  • Jane Anderson
  • Abdel Babiker
  • David Chadwick
  • Valerie Delpech
  • Martin Fisher
  • Brian Gazzard
  • Richard Gilson
  • Mark Gompels
  • Phillip Hay
  • Teresa Hill
  • Margaret Johnson
  • Stephen Kegg
  • Clifford Leen
  • Fabiola Martin
  • Mark Nelson
  • Chloe Orkin
  • Adrian Palfreeman
  • Andrew Phillips
  • Deenan Pillay
  • Frank Post
  • Jillian Pritchard
  • Memory Sachikonye
  • Achim Schwenk
  • Anjum Tariq
  • John Walsh
  • Alicia Thornton
  • Adam Glabay
  • N Perry
  • S Tilbury
  • E Youssef
  • D Churchill
  • R Everett
  • D Asboe
  • S Mandalia
  • H Korat
  • C Taylor
  • Z Gleisner
  • F Ibrahim
  • L Campbell
  • N Brima
  • I Williams
  • M Youle
  • F Lampe
  • C Smith
  • R Tsintas
  • C Chaloner
  • S Hutchinson
  • S Huntington
  • N Mackie
  • A Winston
  • J Weber
  • F Ramzan
  • M Carder
  • J Lynch
  • J Hand
  • C Souza
  • S Munshi
  • S Miller
  • C Wood
  • A Wilson
  • S Morris
  • S Allan
  • A Palfreeman
  • K Memon
  • A ewszuk
  • D Chadwick
  • E Cope
  • J Gibson
  • S Kegg
  • P Main
  • Dr Mitchell
  • Dr Hunter
  • P Hay
  • M Dhillon
  • F Martin
  • S Russell‐Sharpe
  • A Harte
  • S Clay
  • A Tariq
  • H Spencer
  • R Jones
  • C Atkinson
  • V Delpech
  • M Sachikonye
  • Celia Aitken
  • Anton Pozniak
  • Patricia Cane
  • Duncan Clark
  • Simon Collins
  • Samuel Douthwaite
  • Ellen White
  • Christophe Fraser
  • Anna Maria Geretti
  • Antony Hale
  • Stéphane Hué
  • Steve Kaye
  • Paul Kellam
  • Linda Lazarus
  • Andrew Leigh‐Brown
  • Tamyo Mbisa
  • Samuel Moses
  • Eleni Nastouli
  • Erasmus Smit
  • Kate Templeton
  • Peter Tilston
  • Daniel Webster
  • Hongyi Zhang
  • Jane Greatorex
  • Jane Mullen
  • Richard Tandy
  • Tracy Fawcett
  • Mark Hopkins
  • Lynn Ashton
  • Claire Booth
  • Ana Garcia‐Diaz
  • Jill Shepherd
  • Matthias L Schmid
  • Brendan Payne
  • Spiro Pere
  • Jonathan Hubb
  • Stuart Kirk
  • Rory Gunson
  • Amanda Bradley‐Stewart
چکیده

OBJECTIVES No randomized controlled trials have yet reported an individual patient benefit of initiating combination antiretroviral therapy (cART) at CD4 counts > 350 cells/μL. It is hypothesized that earlier initiation of cART in asymptomatic and otherwise healthy individuals may lead to poorer adherence and subsequently higher rates of resistance development. METHODS In a large cohort of HIV-positive individuals, we investigated the emergence of new resistance mutations upon virological treatment failure according to the CD4 count at the initiation of cART. RESULTS Of 7918 included individuals, 6514 (82.3%), 996 (12.6%) and 408 (5.2%) started cART with a CD4 count ≤ 350, 351-499 and ≥ 500 cells/μL, respectively. Virological rebound occurred while on cART in 488 (7.5%), 46 (4.6%) and 30 (7.4%) with a baseline CD4 count ≤ 350, 351-499 and ≥ 500 cells/μL, respectively. Only four (13.0%) individuals with a baseline CD4 count > 350 cells/μL in receipt of a resistance test at viral load rebound were found to have developed new resistance mutations. This compared to 107 (41.2%) of those with virological failure who had initiated cART with a CD4 count < 350 cells/μL. CONCLUSIONS We found no evidence of increased rates of resistance development when cART was initiated at CD4 counts above 350 cells/μL.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure

BACKGROUND The development of HIV drug resistance and subsequent virological failure are often cited as potential disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of duration of infection at the time of initiation. METHODS Patients enrolled in the UK Register of HIV seroconverters were followed-up from cART initiation to last H...

متن کامل

Clinical and Para Clinical Manifestations of HIV-Positive Patients at Different Levels of CD4

Background and Objective: Human immunodeficiency virus (HIV)-infected people are at higher risk of opportunistic infections due to immunodeficiency. The current study aimed to evaluate the different levels of CD4 in HIV-infected patients and its relationship with clinical and paraclinical manifestations of the patients. Materials and Methods: This cross-sectional study was conducted on 94 HIV-...

متن کامل

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

BACKGROUND For patients with human immunodeficiency virus (HIV) infection, structured treatment interruption (STI) is an attractive alternative strategy to continuous treatment, particularly in resource-restrained settings, because it reduces both side effects and costs. One major concern, however, is the development of resistance to antiretroviral drugs that can occur during multiple cycles of...

متن کامل

Significant interaction between activated charcoal and antiretroviral therapy leading to subtherapeutic drug concentrations, virological breakthrough and development of resistance.

A 42-year-old, treatment-experienced woman, virologically suppressed on tenofovir/emtricitabine and boosted atazanavir, experienced virological breakthrough, drop in CD4(+) T-cell count and undetectable drug concentrations. Adherence to treatment was confirmed, but repeat testing yielded similar results. After 2 months, the patient stated that she had been taking activated charcoal to manage ga...

متن کامل

Virological Failure and HIV-1 Drug Resistance Mutations among Naive and Antiretroviral Pre-Treated Patients Entering the ESTHER Program of Calmette Hospital in Cambodia

INTRODUCTION In resource limited settings, patients entering an antiretroviral therapy (ART) program comprise ART naive and ART pre-treated patients who may show differential virological outcomes. METHODS This retrospective study, conducted in 2010-2012 in the HIV clinic of Calmette Hospital located in Phnom Penh (Cambodia) assessed virological failure (VF) rates and patterns of drug resistan...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 17  شماره 

صفحات  -

تاریخ انتشار 2016